The robust Phase 2 data and Blackstone financing significantly de-risk zumilokibart's path to market. Traders should watch for regulatory interactions and Phase 3 initiation in 2H 2026. The pipeline-in-a-product potential (asthma, EoE) adds upside optionality. Monitor upcoming 52-week Part B data and any partnership/out-licensing news.
APGE drugs
APGE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 27 $77.75entry
- T+1 · 6mo ago +0.09%α −0.46% · $77.82
- T+5 · 6mo ago +1.23%α +0.03% · $78.71
- T+20 · 5mo ago +70.65%α +72.55% · $132.68
- T+60 · 3mo ago +73.31%α +71.43% · $134.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics announced positive 16-week Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints with high statistical significance. The mid-dose achieved 65.9% EASI-75 (41.9% placebo-adjusted) and a favorable safety profile, supporting advancement into Phase 3 trials in 2H 2026. A strategic financing collaboration with Blackstone Life Sciences was also announced, expected to fund through commercialization.
Key Facts
- Phase 2 APEX Part B met primary endpoint: mid-dose zumilokibart achieved 65.9% EASI-75 vs 23.4% placebo (p<0.001).
- Key secondary endpoints met: IGA 0/1 46.0% vs 10.9%, EASI-90 47.4% vs 9.3%, I-NRS ≥4 50.5% vs 13.9% (all p<0.001).
- Very Low Disease Activity (vLDA) achieved in 20.6% of mid-dose patients vs 4.5% placebo (p<0.01).
- Safety profile consistent with class; conjunctivitis rate for mid-dose was 10.6% vs 20.7% for high dose.
- Company plans to initiate Phase 3 ADventure trials in AD in 2H 2026, Phase 2b ASPIRE in asthma in 1H 2027, and Phase 2a ELEVATE in EoE in 2H 2026.
- Strategic financing collaboration with Blackstone Life Sciences announced to fund through commercialization.
- Mid-dose selected for Phase 3 based on best clinical activity and tolerability.
Financial Impact
Not disclosed; financing collaboration with Blackstone Life Sciences expected to fund through commercialization of zumilokibart in AD, asthma, and EoE.
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 efficacy or safety results.
- Regulatory interactions could delay or alter Phase 3 trial design.
- Competition from existing IL-13/IL-4Rα biologics (e.g., dupilumab) and emerging therapies.
- Dependence on Blackstone financing terms and potential dilution if additional capital needed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301719 |
Track record
31 reports on APGE
8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers